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Abstract
The comorbidity of type 2 diabetes (T2D) with several psychiatric diseases is well established. While environmental factors
may partially account for these co-occurrences, common genetic susceptibilities could also be implicated in the confluence
of these diseases. In support of shared genetic burdens, TCF7L2, the strongest genetic determinant for T2D risk in the
human population, has been recently implicated in schizophrenia (SCZ) risk, suggesting that this may be one of many loci
that pleiotropically influence both diseases. To investigate whether Tcf7l2 is involved in behavioral phenotypes in addition
to its roles in glucose metabolism, we conducted several behavioral tests in mice with null alleles of Tcf7l2 or overexpressing
Tcf7l2. We identified a role for Tcf7l2 in anxiety-like behavior and a dose-dependent effect of Tcf7l2 alleles on fear learning.
None of the mutant mice showed differences in prepulse inhibition (PPI), which is a well-established endophenotype for
SCZ. These results show that Tcf7l2 alters behavior in mice. Importantly, these differences are observed prior to the onset of
detectable glucose metabolism abnormalities. Whether these differences are related to human anxiety-disorders or
schizophrenia remains to be determined. These animal models have the potential to elucidate the molecular basis of
psychiatric comorbidities in diabetes and should therefore be studied further.
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Introduction
An expanding body of evidence in the literature documents an
increased co-occurrence of type 2 diabetes (T2D) with psychiatric
disorders [1,2,3,4,5,6,7,8,9,10,11,12]. However, the nature of the
underlying co-morbidity is unclear. While one explanation for this
confluence of seemingly unrelated disorders are environmental or
socioeconomic factors such as diet and access to health care, an
alternative possibility is shared genetic susceptibilities indepen-
dently leading to an increased risk of both T2D and psychiatric
disorders.
A potential role for common genetic factors is clearly
documented in the historical comorbidity between T2D and
schizophrenia (SCZ) [13,14]. Though environmental factors, chief
among them the use of antipsychotic medications and in particular
atypical antipsychotic drugs, have been utilized to explain the
increased risk of T2D through weight gain [15], the reported
comorbidity between SCZ and T2D predates the use of
antipsychotics [16,17,18,19,20]. In support of these early obser-
vations, several recent studies have highlighted an enhanced
predisposition to diabetes in drug naı ¨ve schizophrenics
[21,22,23,24,25]. A putative shared genetic burden is further
evidenced through an increased prevalence of T2D in families
affected by schizophrenia [26,27] as well as through linkage studies
for SCZ and T2D that have identified several overlapping
genomic intervals [13]. Taken together, these data support the
possible existence of genetic factors that mediate the co-occurrence
of T2D with other psychiatric disorders.
A recent association study implicated variation within the
Transcription factor 7-like 2 (TCF7L2) gene locus with schizo-
phrenia risk [28]. Importantly, variation in TCF7L2 was previously
associated with T2D risk and is the strongest genetic determinant
for T2D in human populations [29,30,31], Given these genetic
associations, TCF7L2 could serve as a key regulator of both
glucose homeostasis and behavior and consequently represents an
ideal candidate for interrogating the potential role of common
genetic underpinnings in the comorbidity between T2D and
psychiatric disorders.
We have recently developed a Tcf7l2 null allele in mice, and
simultaneously generated transgenic mice overexpressing Tcf7l2
[32]. Our previous analyses defined a direct role for Tcf7l2 on
glucose tolerance and consequently susceptibility to T2D [32].
Here we examined behavior phenotypes in our Tcf7l2 mouse




All mice were housed at the University of Chicago. Veterinary
care was available on a 24-hour basis. Mice were monitored daily
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conducted in strict accordance with institutional rules and
approved by the University of Chicago Institutional Animal Care
and Use Committee, protocol number 71607 (A.A.P.).
Generation of Tcf7l2 knockout and BAC transgenic mice
Tcf7l2 knockout mice were generated using zinc finger
nucleases while Tcf7l2 overexpressing mice were generated using
BAC recombineering as previously described [32]. All three Tcf7l2
knockout lines and only heterozygous null mice (Tcf7l2
+/2) were
used for testing as homozygous null mice displayed perinatal
lethality. Wild-type littermates were utilized as controls for
behavioral testing. Male mice were used for behavioral testing.
Genotyping was conducted as previously outlined [32].
Mouse husbandry
All mice were housed in cages (maximum of 5 animals per cage)
with free access to food and water. Animals at 6–7 weeks of age
were transferred for behavioral testing. After transfer, mice were
allowed to acclimate to the new environment for at least 1 week
prior to testing. For all behavioral tests, mice were transferred
from the vivarium in home cages to the testing room and allowed
to acclimate for 30 min prior to testing.
Open field testing
The open field consisted of a 40640640 cm Plexiglas chamber
under bright illumination (,300 lux). After acclimation, mice
were placed into the center (20620 cm) of the open field. For 5
minutes, behavior was recorded and automatically scored using
Ethovision XT (Noldus, Wageningen, Netherlands).
Light dark box testing
The light-dark box apparatus consisted of the open field
chamber described above, bisected by a black Plexiglas insert
(20640640 cm) with a 464 cm door that allowed mice to explore
both dark and light areas. After acclimation, mice were placed in
the light compartment, and activity was monitored for 5 minutes.
Behavior was recorded and automatically scored using Ethovision
XT (Noldus, Wageningen, Netherlands).
Fear conditioning
Fear conditioning was a 3-day paradigm and has previously
been described in detail [33]. Fear conditioning occurred in
standard conditioning chambers (29619625 cm with a stainless
steel floor grid; Med Associates, St. Albans, VT, USA) with a light
on the top of the chamber providing dim illuminations (,3 lux).
Each chamber was housed within a sound-attenuated chamber
with a vent fan on one wall providing masking of background
noise in the testing room. Freezing was digitally recorded and
analyzed with FreezeFrame software (Actimetrics, Wilmette, IL,
USA).
Day 1: Mice were placed in the test chamber (MedAssociates),
and baseline freezing was measured. Mice were exposed to a tone
twice (30 seconds, 85 dB, 3 kHz) that co-terminated with a
footshock (2 seconds, 0.5 mA). A 30-second interval separated the
two tone-footshock pairings.
Day 2: Test conditions were identical to day 1, but neither tone
nor footshocks were presented.
Day 3: The chamber was altered in several ways: a different
experimenter wore a different style of gloves; the transfer cages
had no bedding; the metal shock grid was covered with a gray
plastic floor; a bent gray plastic wall was inserted into the test
chamber; a yellow light filter was placed over the chamber lights;
chambers were cleaned with 0.1% acetic acid solution; and the
vent fan was partially obstructed to change the background noise.
The tone was presented at the same times as on day 1, but no foot
shock was administered.
Prepulse Inhibition
Startle chambers consisted of nonrestrictive Plexiglas cylinders
5 cm in diameter resting on a Plexiglas platform in a ventilated
chamber (San Diego Instruments, San Diego, CA) as described
elsewhere [34]. Sixty-five consecutive 1-ms readings were recorded
beginning at startle stimulus onset to obtain the amplitude of the
animals’ startle response to each stimulus [34]. Sound levels were
measured as described elsewhere using the A weighting scale [35].
For each test session, mice were exposed to five different trials: a
40-msec broadband 120 dB burst (Pulse Alone trial); three
different Prepulse + Pulse trials in which either 20-msec long
3 dB, 6 dB, or 12 dB above background stimuli preceded
the120 dB pulse by 100 msec (onset to onset); and a No Stimulus
trial, in which only background noise (65 dB) was presented. Trials
were presented in a pseudo-random order and separated by an
average of 15 s (range: 9–20 s). The test session began with a 5-
min acclimation period, which was followed by four blocks of test
trials. Blocks one and four consisted of six consecutive Pulse Alone
trials, while blocks two and three each contained six Pulse Alone
trials, five of each kind of Prepulse + Pulse trial, and four No
Stimulus trials. Prepulse inhibition (PPI) was calculated as [100 –
(Prepulse—Pulse trial/averaged Pulse Alone)6100]. Pulse Alone
values were calculated as the mean of startle values from blocks
two and three. ANOVAs with genotype as a between-subjects
factor, and block and prepulse intensity as within-subject factors
were applied to averaged PPI values. For startle reactivity,
ANOVAs with genotype as a between-subjects factor was applied
to averaged Pulse Alone values from blocks two and three to
determine whether any effects of these variables on startle
confounded the interpretation of PPI results.
Statistical tests
Data are shown as mean 6 standard error of the mean (S.E.M).
An unpaired two-sided Student’s t-test was utilized to test for
significance in the open field, light dark box and fear conditioning.
For PPI, a repeated measures ANOVA was used with PPI
intensity as the repeated measure and genotype as single factor.
Results
Open field Testing
To elucidate a role for Tcf7l2 in anxiety-like behavior, adult
heterozygous null mice (Tcf7l2
+/2) were first tested in the open
field. Tcf7l2
+/2 mice exhibited decreased time in the center of the
arena compared to wild-type littermates (P,0.005; Figure 1A).
Analysis of total distance between knockout mice and their wild-
type littermates identified a significant decrease in locomotor
activity (p,0.0001; Figure 1B). Further, latency to periphery was
not significantly different between the two groups of mice
(p=0.93; Figure 1C).
During open-field testing, adult BAC transgenic mice overex-
pressing Tcf7l2 did not show significant differences in center time
(p=0.39; Figure 2A), locomotor activity (p=0.90; Figure 2B), or
latency to periphery (p=0.53; Figure 2C) compared to wild-type
littermates.
Light dark box testing
To further investigate the role of Tcf7l2 in anxiety-like behavior
we tested mice in the light dark box. Tcf7l2
+/2 mice spent
Tcf7l2 Alters Behavior in Mice
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wild-type littermates (p,0.05; Figure 1D). Tcf7l2
+/2 mice did not
differ from their wild-type litter mates in the number of transitions
between the light and dark compartments (p=0.22; Figure 1E)
and latency to dark was not significantly different between the two
groups of animals (p=0.58; Figure 1F).
We next tested BAC transgenic mice in the light dark box.
Similar to the open field test results, we did not observe significant
differences in time spent in the light compartment (p=0.51;
Figure 2D). Further, no significant differences were detected in the
number of transitions between the light and dark compartments
(p=0.37; Figure 2E) or the latency to transition to the dark
compartment (p=0.47; Figure 2F).
Fear Conditioning
We also explored fear conditioning in the Tcf7l2
+/2 mice. Fear
conditioning measures learned fear and is correlated with
differences in anxiety-like behavior [33]. Tcf7l2
+/2 mice displayed
increased freezing to both context (p,0.05; Figure 1G) and tone
(p,0.05; Figure 1H). Importantly, pre-training freezing was not
significantly different between the two groups (p=0.83; Figure 1I),
suggesting that alterations in generalized freezing behavior were
not responsible for the observed differences.
BAC transgenic mice subsequently underwent fear condition-
ing. Surprisingly, we identified a reciprocal phenotype in our BAC
transgenic mice compared to the Tcf7l2
+/2 mice. Overexpression
of Tcf7l2 significantly decreased freezing to context (p=0.05,
Figure 2G). Freezing to the tone was not significantly different
between BAC transgenic mice and wild-type littermates (p=0.28,
Figure 2H). This suggests that Tcf7l2 overexpression increases
contextual, but not cue-based fear. Importantly, pre-training
freezing was not significantly different between the two groups
(p=0.91, Figure 2I), indicating that baseline differences in freezing
do not confound the results.
Prepulse Inhibition
There were no differences in prepulse inhibition (PPI) (Figures 1J
and 2J). Importantly, both genotypes showed increasing levels of
PPI as the prepulse intensities increased, demonstrating that the
startle response in these animals was effectively modulated by the
prepulses. Startle responses between animals were not significantly
different (Figures 1K and 2K).
Discussion
To functionally test the hypothesis that the observed co-
morbidity between T2D and psychiatric disorders might be
partially due to pleiotropic effects of TCF7L2 alleles, we performed
several behavioral studies using mice with null alleles of Tcf7l2 as
well as mice over-expressing Tcf7l2. The use of these mouse
models allowed for the testing of a range of Tcf7l2 copy numbers
that might be similar to gain- or loss-of-function alleles in humans.
Our data support a role for Tcf7l2 in behavior, thereby
demonstrating that this transcription factor can influence a diverse
set of processes.
Using the open field and light dark box tests, we observed
anxiety-like phenotypes in Tcf7l2
+/2 mice; ablation of Tcf7l2 led
to decreased time in the center of the arena and in the light
compartment. However, these phenotypes were coincident with
differences in locomotor activity, namely decreased distance
traveled in the open field. While this may confound the
interpretation of anxiety phenotypes, we did not observe
significant differences in latency to periphery in open field testing.
Both latency to the dark compartment and the number of
transitions were not significant in light dark box testing, suggesting
this test might not have been confounded by differences in activity.
Taken together, these observations support a role for Tcf7l2 in
anxiety-like behaviors; future studies of the impact of human
alleles of TCF7L2 on anxiety are warranted.
Our mouse model demonstrated a dose-dependent role for
Tcf7l2 in fear learning. Ablation of Tcf7l2 led to enhanced fear
learning while mice overexpressing Tcf7l2 displayed an impair-
ment of fear learning. Interestingly, this gene-dosage effect was
only observed for contextual fear, which is believed to be a
hippocampus-dependent process [36] and therefore may have
some relevance for SCZ. Indeed, disruptions of contextual
processing are known to occur in SCZ [37] and this endopheno-
type is routinely used in rodent and human studies [38,39].
While our study uncovered a role for Tcf7l2 on anxiety and fear
learning, we did not identify significant differences in PPI in both
heterozygous null mice and BAC transgenic mice. This is
significant because PPI is a behavioral test that can be more
directly related to the observation of increased risk for SCZ in
humans [28]. However, we cannot exclude potential differences in
PPI in older mice as behavioral studies were conducted on mice 7–
8 weeks of age at the start of behavioral testing.
Importantly, none of the mice were diabetic during behavioral
testing as we previously reported glucose intolerance in mice
overexpressing Tcf7l2 only after a high fat diet stress [32]. As a
result, this enabled the dissociation of diabetes-related secondary
effects in this study. In light of this, our study design is able to
detect independent genetic effects on behavior, which is a
significant advantage over studies of co-morbidity in humans.
Our design allows us to conclude that Tcf7l2 directly regulates
behavior.
The idea that seemingly disparate diseases may result from
shared susceptibility loci is intriguing and reflects the integrated
nature of our genome. Indeed, TCF7L2 functions as a transcrip-
tional regulator of the canonical Wnt signaling pathway that
maintains broad roles in development regulating cell fate, survival
and proliferation [40,41,42]. Genes such as TCF7L2 that are
involved in pathways that harbor pleiotropic functions represent
strong candidates in this respect. Our study demonstrates that
TCF7L2 carries pleiotropic effects and provides added evidence of
Figure 1. Behavioral analyses from Tcf7l2 ablation. (A)–(C) Open field testing. (A) Center time shown as a percent of total time (%) in wild-type
(WT, n=14) and heterozygous null (+/2, n=12) mice. (B) Total distance shown in meters (m) in wild-type (WT, n=14) and heterozygous null (+/2,
n=12) mice. (C) Latency to periphery shown in seconds (s) in wild-type (WT, n=14) and heterozygous null (+/2, n=12) mice. (D)–(F) Light dark box
testing. (D) Time in light shown as percent of total time (%) in wild-type (WT, n=14) and heterozygous null (+/–, n=12) mice. (E) Number of
transitions between the light and dark compartments in wild-type (WT, n=14) and heterozygous null (+/–, n=12) mice. (F) Latency to the dark
compartment shown in seconds (s) in wild-type (WT, n=14) and heterozygous null (+/–, n=12) mice. (G)–(I) Fear conditioning. (G) Contextual fear
shown as a percent time spent freezing (%) in wild-type (WT, n=14) and heterozygous null (+/–, n=12) mice. (H) Cue-based fear shown as a percent
time spent freezing (%) in wild-type (WT, n=14) and heterozygous null (+/–, n=12) mice. (I) Pre-training freezing shown as a percent time spent
freezing (%) in wild-type (WT, n=14) and heterozygous null (+/–, n=12) mice. (J) Prepulse inhibition in wild-type (WT, n=14) and heterozygous null
(+/–, n=12) mice. Prepulse inhibition (%) using prepulses of 3, 6 and 12 decibels (dB) are shown. (K) Startle response in wild-type (WT, n=14) and
heterozygous null (+/–, n=12) mice. Wild-type data are shown in gray while heterozygous null data are shown in blue.
doi:10.1371/journal.pone.0026897.g001
Tcf7l2 Alters Behavior in Mice
PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26897Tcf7l2 Alters Behavior in Mice
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26897possible common genetic underpinning that may explain the
historical comorbidities between T2D and psychiatric disorders.
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Figure 2. Behavioral analyses from Tcf7l2 overexpression. (A)–(C) Open field testing. (A) Center time shown as a percent of total time (%) in
wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. (B) Total distance shown in meters (m) in wild-type (WT, n=9) and BAC transgenic (BAC,
n=9) mice. (C) Latency to periphery shown in seconds (s) in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. (D)–(F) Light dark box testing.
(D) Time in light shown as a percent of total time (%) in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. (E) Number of transitions between
the light and dark compartments in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. (F) Latency to the dark compartment shown in
seconds (s) in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. (G) – (I) Fear conditioning. (G) Contextual fear shown as a percent time spent
freezing (%) in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. (H) Cue-based fear shown as a percent time spent freezing (%) in wild-type
(WT, n=9) and BAC transgenic (BAC, n=9) mice. (I) Pre-training freezing shown as a percent time spent freezing (%) in wild-type (WT, n=9) and BAC
transgenic (BAC, n=9) mice. (J) Prepulse inhibition in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. Prepulse inhibition (%) using
prepulses of 3, 6 and 12 decibels (dB) are shown. (K) Startle response in wild-type (WT, n=9) and BAC transgenic (BAC, n=9) mice. Wild-type data are
shown in gray while BAC transgenic data are shown in orange.
doi:10.1371/journal.pone.0026897.g002
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